Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

Genet,Stefan  C.; Maeda,Junko; Fujisawa,Hiroshi; Yurkon,Charles  R.; Fujii,Yoshihiro; Romero,Ashley  M.; Genik,Paula  C.; Fujimori,Akira; Kitamura,Hisashi; Kato,Takamitsu  A.

doi:10.3892/or.2012.1982

Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

Authors:
- Stefan C. Genet
- Junko Maeda
- Hiroshi Fujisawa
- Charles R. Yurkon
- Yoshihiro Fujii
- Ashley M. Romero
- Paula C. Genik
- Akira Fujimori
- Hisashi Kitamura
- Takamitsu A. Kato
View Affiliations

Affiliations: Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA, National Institute of Radiological Sciences, Research Center for Charged Particle Therapy, Molecular Target Research Unit, Chiba 263-8555, Japan , National Institute of Radiological Sciences, Research Center for Charged Particle Therapy, Molecular Target Research Unit, Chiba 263-8555, Japan , Research Development and Support Center, Inage, Chiba 263-8555, Japan
Published online on: August 22, 2012 https://doi.org/10.3892/or.2012.1982
Pages: 1591-1596

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Charged particle therapy utilizing protons or carbon ions has been rapidly intensifying over recent years. The present study was designed to jointly investigate these two charged particle treatment modalities with respect to modeled anatomical depth-dependent dose and linear energy transfer (LET) deliveries to cells with either normal or compromised DNA repair phenotypes. We compared cellular lethality in response to dose, LET and Bragg peak location for accelerated protons and carbon ions at 70 and 290 MeV/n, respectively. A novel experimental live cell irradiation OptiCell™ in vitro culture system using three different Chinese hamster ovary (CHO) cells as a mammalian model was conducted. A wild-type DNA repair-competent CHO cell line (CHO 10B2) was compared to two other CHO cell lines (51D1 and xrs5), each genetically deficient with respect to one of the two major DNA repair pathways (homologous recombination and non-homologous end joining pathways, respectively) following genotoxic insults. We found that wild-type and homologous recombination-deficient (Rad51D) cellular lethality was dependent on both the dose and LET of the carbon ions, whereas it was only dependent on dose for protons. The non-homologous end joining deficient cell line (Ku80 mutant) showed nearly identical dose-response profiles for both carbon ions and protons. Our results show that the increasingly used modality of carbon ions as charged particle therapy is advantageous to protons in a radiotherapeutic context, primarily for tumor cells proficient in non-homologous end joining DNA repair where cellular lethality is dependent not only on the dose as in the case of more common photon therapeutic modalities, but more importantly on the carbon ion LETs. Genetic characterization of patient tumors would be key to individualize and optimize the selection of radiation modality, clinical outcome and treatment cost.

View Figures

View References

1	Ares C, Hug EB, Lomax AJ, et al: Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 75:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hug EB and Slater JD: Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am. 11:627–638. 2000.PubMed/NCBI
3	Pontvert D: Value of proton therapy in tumors other than melanomas of the eye and sarcomas of the base of the skull. Pathol Biol. 41:1181993.(In French).
4	Munzenrider JE and Liebsch NJ: Proton therapy for tumors of the skull base. Strahlenther Onkol. 175(Suppl 2): 57–63. 1999. View Article : Google Scholar : PubMed/NCBI
5	St Clair WH, Adams JA, Bues M, et al: Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys. 58:727–734. 2004.PubMed/NCBI
6	Timmermann B: Proton beam therapy for childhood malignancies: status report. Klin Padiatr. 222:127–133. 2010. View Article : Google Scholar : PubMed/NCBI
7	Hattangadi JA, Rombi B, Yock TI, et al: Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int J Radiat Oncol Biol Phys. Dec 2–2011.(Epub ahead of print).
8	Mizoe JE, Hasegawa A, Jingu K, et al: Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 103:32–37. 2012. View Article : Google Scholar : PubMed/NCBI
9	Ishikawa H, Tsuji H, Kamada T, et al: Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 81:57–64. 2006. View Article : Google Scholar : PubMed/NCBI
10	Combs SE, Kalbe A, Nikoghosyan A, et al: Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol. 98:63–67. 2011. View Article : Google Scholar
11	Silari M: Applications of particle accelerators in medicine. Radiat Prot Dosimetry. 146:440–450. 2011. View Article : Google Scholar
12	Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al: Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 58:631–640. 2004. View Article : Google Scholar : PubMed/NCBI
13	Akutsu Y, Yasuda S, Nagata M, et al: A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 105:750–755. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhang H, Li S, Wang XH, et al: Results of carbon ion radiotherapy for skin carcinomas in 45 patients. Br J Dermatol. 166:1100–1106. 2012. View Article : Google Scholar : PubMed/NCBI
15	Paganetti H, Niemierko A, Ancukiewicz M, et al: Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 53:407–421. 2002. View Article : Google Scholar : PubMed/NCBI
16	Rodriguez-Lafrasse C and Balosso J: From the carbon track to therapeutic efficiency of hadrontherapy. Cancer Radiother. 16:16–24. 2012.PubMed/NCBI
17	Terasawa T, Dvorak T, Ip S, Raman G, Lau J and Trikalinos TA: Systematic review: charged-particle radiation therapy for cancer. Ann Intern Med. 151:556–565. 2009. View Article : Google Scholar : PubMed/NCBI
18	Carabe A, Moteabbed M, Depauw N, Schuemann J and Paganetti H: Range uncertainty in proton therapy due to variable biological effectiveness. Phys Med Biol. 57:1159–1172. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tsunemoto H, Morita S, Ishikawa T, et al: Proton therapy in Japan. Radiat Res (Suppl). 8:S235–S243. 1985. View Article : Google Scholar
20	Wouters BG, Lam GK, Oelfke U, Gardey K, Durand RE and Skarsgard LD: Measurements of relative biological effectiveness of the 70 MeV proton beam at TRIUMF using Chinese hamster V79 cells and the high-precision cell sorter assay. Radiat Res. 146:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
21	Weyrather WK and Kraft G: RBE of carbon ions: experimental data and the strategy of RBE calculation for treatment planning. Radiother Oncol. 73(Suppl 2): S161–S169. 2004. View Article : Google Scholar : PubMed/NCBI
22	Peschke P, Karger CP, Scholz M, Debus J and Huber PE: Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat. Int J Radiat Oncol Biol Phys. 79:239–246. 2011. View Article : Google Scholar : PubMed/NCBI
23	Cui X, Oonishi K, Tsujii H, et al: Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays. Cancer Res. 71:3676–3687. 2011. View Article : Google Scholar : PubMed/NCBI
24	Frese MC, Yu VK, Stewart RD and Carlson DJ: A mechanism-based approach to predict the relative biological effectiveness of protons and carbon ions in radiation therapy. Int J Radiat Oncol Biol Phys. 83:442–450. 2012. View Article : Google Scholar : PubMed/NCBI
25	Ando K and Kase Y: Biological characteristics of carbon-ion therapy. Int J Radiat Biol. 85:715–728. 2009. View Article : Google Scholar : PubMed/NCBI
26	Jeggo PA and Kemp LM: X-ray-sensitive mutants of Chinese hamster ovary cell line. Isolation and cross-sensitivity to other DNA-damaging agents. Mutat Res. 112:313–327. 1983.PubMed/NCBI
27	Hinz JM, Tebbs RS, Wilson PF, et al: Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res. 34:1358–1368. 2006. View Article : Google Scholar : PubMed/NCBI
28	Weyrather WK, Ritter S, Scholz M and Kraft G: RBE for carbon track-segment irradiation in cell lines of differing repair capacity. Int J Radiat Biol. 75:1357–1364. 1999. View Article : Google Scholar : PubMed/NCBI
29	Elsasser T, Weyrather WK, Friedrich T, et al: Quantification of the relative biological effectiveness for ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and a novel approach for treatment planning. Int J Radiat Oncol Biol Phys. 78:1177–1183. 2010. View Article : Google Scholar
30	Belli M, Cera F, Cherubini R, et al: RBE-LET relationships for cell inactivation and mutation induced by low energy protons in V79 cells: further results at the LNL facility. Int J Radiat Biol. 74:501–509. 1998. View Article : Google Scholar : PubMed/NCBI